Noticias y Eventos

Descubra las novedades en el campo de las patologías oculares hereditarias

Blog operado por el equipo de DBGen que actualiza terapias, noticias y eventos relacionados con las enfermedades hereditarias oculares. Le invitamos a participar en este foro.

Filters

Category list

Leber Congenital Amaurosis DBGen Genetic Diagnosis Retinal Dystrophy Research Mutation Patients Stargardt Gene Therapy

Entry date

August 2019 (2)

July 2019 (1)

June 2019 (2)

May 2019 (1)

April 2019 (2)

March 2019 (2)

February 2019 (1)

January 2019 (1)

December 2018 (2)

October 2018 (2)

September 2018 (1)

July 2018 (2)

May 2018 (2)

April 2018 (3)

March 2018 (2)

February 2018 (3)

January 2018 (2)

December 2017 (1)

Subscribe to our blog

New RNA therapy for autosomal dominant retinitis pigmentosa

27/08/19 - Retinal Dystrophy, Gene Therapy,

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form of autosomal dominant retinitis pigmentosa (RPad) caused by the P23H mutation in the rhodopsin gene (RHO). QR-1123 is an antisense oligonucleotide, that is, a short RNA...

A race against the clock for Leber congenital amaurosis gene therapy

14/08/19 - Leber Congenital Amaurosis, Retinal Dystrophy, Gene Therapy,

ProQR Sepofarsen therapy On July 29, the Dutch company ProQR announced that the European Medicines Agency (EMA) has granted access to the Agency's priority medicine program (PRIME) to its Sepofarsen therapy (QR-110), designed for the treatment of Leber congenital amaurosis (LCA10), a childhood blinding disorder, caused by the c.2991+1655A>G (p.Cys998 *) mutation in the CEP290 gene. The EMA PRIME program...

DBGen and the UB-CIBERER U-718 group present their current research in genetic diagnosis and animal models of inherited retinal dystrophies in ARVO 2019

13/05/19 - DBGen, Genetic Diagnosis, Retinal Dystrophy, Research, Gene Therapy,

Dr. Gemma Marfany (co-founder and scientific board member of DBGen) presented an oral communication in ARVO 2019 (held in Vancouver, 2-6 May) to show the most prominent results of the research that his group at the UB-CIBERER (U-718) and DBGEN are currently undertaking to study inherited retinal dystrophies. This work is focused on improved genetic diagnosis and the generation of...

RPGeNet v2.0 allows visualizing interactions of more than 270 causative genes of inherited retinal dystrophies

30/04/19 - Retinal Dystrophy, Research,

RPGeNet is a network dedicated to provide a graphical platform that links retinal dystrophies causative genes with their molecular interactors. The aim of this network is granting researchers a tool that allows them to understand the pathological process in its cellular and histological context, highlight key molecular players of retinal degeneration and unveil new candidate genes of these diseases (Boloc...

First patient treated in ProQR STELLAR phase 1/2 gene therapy clinical trial for Usher Syndrome Type II

13/03/19 - Retinal Dystrophy, Research, Gene Therapy,

Usher syndrome is a genetic disorder that presents recessive inheritance and is characterized by hearing loss and retinitis pigmentosa, traits that may be total or partial. The prevalence of this disease is 1: 30,000 individuals considering the three types of USHER identified, the most common being type II (60% of cases), caused mostly by the USH2A gene. There was no...

Relevance of the identification and characterization of deep-intronic mutations

19/02/19 - Genetic Diagnosis, Retinal Dystrophy, Research, Mutation, Patients,

Genes are DNA sequences that contain information for the synthesis of proteins and they are composed of exonic and intronic sequences. The exons possess the information used for the protein synthesis, whereas the introns, although they do not contain information translated into protein, they play an important role to ensure their correct formation. Each gene has several exons interspersed between...

1 2 >